E
Exicure
Exicure is developing a new class of immunomodulatory and gene silencing drugs against validated targets
About Exicure
Exicure, Inc. is a biotechnology company pioneering the development of nucleic acid-based therapeutics aimed at treating rare and severe genetic diseases and cancer. Utilizing their proprietary Spherical Nucleic Acid (SNA) technology, Exicure enables the delivery of genetically targeted therapies to a wide range of tissues and cells. This technology has demonstrated potential applications in preclinical studies for the central nervous system (CNS), eye, lung, and gastrointestinal (GI) tract.
Read full description
Exicure operates in the biopharmaceutical market, primarily serving patients with unmet medical needs due to rare genetic disorders and various forms of cancer. The company's business model revolves around the research, development, and eventual commercialization of its therapeutic candidates. Revenue generation is expected through partnerships, licensing agreements, and future sales of approved therapies.
Exicure's SNA technology overcomes significant challenges in the delivery of nucleic acid therapeutics, offering high transfection efficiency into numerous cell and tissue types without the need for carriers or transfection agents. This positions the company at the forefront of innovative treatment solutions in the biotech industry.
At a glance
- Founded
- 2009
- Headquarters
- Chicago, United States
- Listing
- IPO 2018
- Sector
- Biotech & Life Sciences
Latest news
Press, funding announcements and product moves mentioning Exicure.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A7 investors entered at this stage
Eric Schmidt
David R. Walt
Patrick Ryan
Abbvie Biotech Ventures- AVAbbott Biotech Ventures
Craig Mundie
AbbVie
Series B and later7 investors entered at this stage
Boon Hwee Koh
Bill Gates
Alumni Ventures
Purple Arch Ventures (an Alumni Ventures Fund)
The Yard Ventures
Silicon Valley Bank
Midcap Financial
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Exicure on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Exicure on the full Dealroom platform
Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.